Search

Displaying results 8241 - 8250 of 10000 in total
  1. Drug

    GT 389-255

    go.drugbank.com/drugs/DB05894
    Experimental

    Peptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and MAD) Phase I trials. It is expected...

  2. Drug

    HMR4011

    go.drugbank.com/drugs/DB06225
    Experimental

    HMR4011 (IPL 576,092) is a novel steroidal anti-inflammatory compound with a mechanism of action distinct from that of glucocorticoid. IPL 576,092 has previously been investigated as a treatment for asthma.

  3. Drug

    MAHDL01

    go.drugbank.com/drugs/DB06270
    Experimental

    MAHDL01 is a pharmaceutical combination of whole plants, which is used to increase the HDL/LDL ratio that improves overall cardiovascular health.

  4. Drug

    Semuloparin

    go.drugbank.com/drugs/DB06294
    Investigational

  5. Drug

    R107474

    go.drugbank.com/drugs/DB06553
    Experimental

  6. Drug

    P-57AS3

    go.drugbank.com/drugs/DB06569
    Experimental

  7. Drug

    Enokizumab

    go.drugbank.com/drugs/DB05555
    Investigational

    A humanized immunoglobulin G1k anti-interleukin-9 mAb.

  8. Drug

    Tulrampator

    go.drugbank.com/drugs/DB16344
    Investigational

    Tulrampator is under investigation in clinical trial NCT02626572 (Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive

  9. Drug

    Ichorcumab

    go.drugbank.com/drugs/DB18930
    Investigational

    Ichorcumab is under investigation in clinical trial NCT03251482 (A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee

  10. Drug

    GO-203-2C

    go.drugbank.com/drugs/DB15008
    Investigational

    GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).